Stocktoria
Enovis CORP ENOV
NYSE · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies · website · IPO 2008-05-08 · LEI
Enovis CORP financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $2.1B | $1.7B | $1.6B | $1.4B | $1.1B | $3.3B | $3.7B | $3.3B | $3.2B |
| Gross profit | $1.3B | $1.2B | $990.8M | $869.4M | $777.7M | $603.6M | $1.4B | $729.4M | $671.6M | $992.4M |
| R&D expense | $120.3M | $91.3M | $75.3M | $60.8M | $49.1M | $34.3M | — | — | — | — |
| SG&A expense | $1.1B | $1.0B | $830.3M | $772.9M | $665.8M | $515.5M | $1.1B | $548.8M | $500.6M | $696.8M |
| Operating income | -$1.1B | -$775.7M | -$65.7M | -$71.2M | -$62.8M | -$66.2M | $203.6M | $151.5M | $135.6M | $236.8M |
| Interest expense | $34.8M | $57.1M | $19.7M | $24.1M | $29.1M | $52.8M | $119.5M | $49.1M | $40.1M | $30.3M |
| Income tax | $22.3M | $4.5M | -$13.3M | $36.1M | -$19.5M | -$44.6M | $31.6M | -$29.5M | $2.5M | $51.8M |
| Net income | -$1.2B | -$825.5M | -$33.3M | -$13.3M | $71.7M | $42.6M | -$527.6M | $140.2M | $151.1M | $128.1M |
| EPS (diluted) | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.40 | $0.93 | $-3.89 | $1.16 | $1.22 | $1.04 |
| Operating cash flow | $217.3M | $113.5M | $135.0M | -$55.9M | $356.1M | $301.9M | $130.9M | $226.4M | $218.8M | $247.0M |
| Free cash flow | $19.9M | -$67.2M | $12.8M | -$161.3M | $251.9M | $187.2M | $5.5M | $156.7M | $150.0M | $183.7M |
| Cash & equivalents | $36.4M | $48.2M | $36.2M | $24.3M | $680.3M | $97.1M | $109.6M | $77.2M | $262.0M | $208.8M |
| Inventory | $584.4M | $547.1M | $468.8M | $426.6M | $356.2M | $564.8M | $571.6M | $359.7M | $429.6M | $365.0M |
| Total assets | $3.8B | $4.7B | $4.5B | $4.3B | $8.5B | $7.4B | $7.4B | $6.6B | $6.7B | $6.3B |
| Total liabilities | $2.3B | $2.2B | $1.1B | $823.4M | $3.9B | $3.8B | $3.9B | $3.1B | $3.0B | $3.2B |
| Shareholders' equity | $1.5B | $2.6B | $3.4B | $3.4B | $4.7B | $3.6B | $3.5B | $3.5B | $3.7B | $3.1B |
Growth · year-over-year · Revenue CAGR -3.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +6.7% | +23.5% | +9.2% | +9.6% | +27.3% | -66.3% | -9.3% | +11.1% | +3.6% | -7.2% |
| Net income growth | — | — | — | -118.5% | +68.1% | — | -476.4% | -7.2% | +17.9% | -23.6% |
| EPS growth | — | — | — | -117.9% | +50.5% | — | -435.3% | -4.9% | +17.3% | -22.4% |
| Free cash flow growth | — | -626.5% | — | -164.0% | +34.6% | +3274.5% | -96.5% | +4.5% | -18.4% | -21.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.